Why the study?
Systolic ejection time and systemic inflammation are two essential indicators of heart failure progression, motivating evaluation of their relationship in end-stage heart failure.
Is systolic ejection time associated with systemic inflammation in patients with end-stage heart failure?
Is systolic ejection time associated with systemic inflammation in patients with end-stage heart failure?
Reduced systolic ejection time correlates with increased systemic inflammation in end-stage heart failure, suggesting its potential utility in risk stratification.
Answers are grounded in this paper and cite their sources.
Shorter SET was associated with higher CRP and select chemokines in end-stage HF; hypothesis-generating for risk stratification and requires prospective validation.
OBJECTIVES: Systolic ejection time (SET) and systemic inflammation are two essential indicators of heart failure (HF) progression. We aimed to evaluate the associations between SET and inflammatory mediators in end-stage HF. METHODS: Participants included 16 patients with end-stage HF recruited from the Heart Failure Clinic at Toronto General Hospital and 16 healthy individuals free of any known cardiovascular disease. SET, end systolic pressure, and levels of inflammatory mediators were documented for each patient, and a Spearman rank correlation coefficient was performed to examine differences between patients with end-stage HF and healthy controls. The levels of other inflammatory mediators-granulocyte-stimulating factor, granulocyte-macrophage colony-stimulating factor, interleukin-8, macrophage inflammatory protein-1, macrophage inflammatory protein-1α, and tumor necrosis factor α-were not significantly correlated with SET. CONCLUSIONS: We found that SET was significantly lower in patients with end-stage HF compared with healthy controls and that reduced SET correlated with increased levels of several inflammatory mediators in patients with HF. By better understanding the relationship between SET and inflammation in HF, a more thorough evaluation could lead to improved risk stratification among patients with HF. Future work should investigate the roles of SET and inflammation in HF.
No takes yet. Share an insight, caveat, or question.
Gutovitz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: